Biodexa Pharmaceuticals (BDRX) Liabilities and Shareholders Equity (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $24.2 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 27.47% year-over-year to $24.2 million; the trailing twelve-month figure through Dec 2025 stood at $80.6 million (up 35.05% YoY), and the FY2025 full-year result was $24.0 million, up 26.35% from the prior year.
• Liabilities and Shareholders Equity improved to $24.2 million in Q4 2025, from $19.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $24.2 million in Q4 2025 to a low of $6.5 million in Q4 2022.
• A 5-year average of $15.1 million and a median of $15.2 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity plunged 62.77% in 2022 and jumped 101.9% in 2023, its largest moves.
• Tracing BDRX's Liabilities and Shareholders Equity over 5 years: stood at $17.4 million in 2021, then sank by 62.77% to $6.5 million in 2022, then soared by 101.9% to $13.1 million in 2023, then soared by 44.98% to $19.0 million in 2024, then rose by 27.47% to $24.2 million in 2025.
• Business Quant data shows BDRX's Liabilities and Shareholders Equity at $24.2 million in Q4 2025, $19.8 million in Q2 2025, and $19.0 million in Q4 2024.